殷康

中国医学科学院阜外医院 心律失常中心

Electrical Storm in ICD Recipients with Arrhythmogenic Right Ventricular Cardiomyopathy.

BACKGROUND:Implantable cardioverter defibrillator (ICD) is the most important management for prevention of sudden cardiac death (SCD) in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). However, some patients may receive multiple ICD therapies in a short period, a condition referred as "electrical storm" (ES).OBJECTIVES:This study aimed to determine the prevalence, therapeutic options, and prognostic implications of ES in ARVC patients with an ICD.METHODS:We retrospectively analyzed the baseline and follow-up data of 39 ARVC patients with an ICD. ES was defined as three or more separated episodes of ventricular tachycardia or ventricular fibrillation (VT/VF) within a 24-hour period.RESULTS:During a median follow-up of 49 months (range 6-225), 12 of 39 (31%) patients suffered at least one episode of ES. The interval between the first ES and the initial ICD implantation ranged from 1 month to 109 months, and ES was the first ICD discharge in three patients. The median number of VT/VF events per ES was four (range 3-39). Five patients experienced 20 episodes of ES that were treated by antitachycardia pacing only, while the other seven patients suffered shock therapies during ES. In three patients, ES required emergency hospitalization, and the repeatedly occurred VT/VF was finally subsided by intravenous amiodarone. There was no significant difference in actual survival between patients with and without such an event.CONCLUSIONS:ES is not rare in ARVC patients with an ICD for prevention of SCD, but it does not independently confer increased mortality. Intravenous amiodarone is effective in management of ES when VT/VF repeatedly occurred.

1.8
4区
第一作者

Pacing and clinical electrophysiology : PACE 2017

Long-term follow-up of arrhythmogenic right ventricular cardiomyopathy patients with an implantable cardioverter-defibrillator for prevention of sudden cardiac death.

BACKGROUND:Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare inherited cardiomyopathy with a high burden of ventricular arrhythmia, which is an important cause of sudden cardiac death (SCD). Implantable cardioverter-defibrillator (ICD) is believed to be the most reliable management against SCD.HYPOTHESIS:Ventricular arrhythmia does not necessarily confer a poor prognosis in ARVC patients with an ICD.METHODS:A total of 39 ARVC patients (34 male) implanted with an ICD at our electrophysiology center and followed up continuously were included in this study. The mean age at diagnosis was 42.1 ± 14.8 years.RESULTS:Thirty-three patients (84.6%) had suffered ventricular arrhythmia with hemodynamic compromise before ICD implantation. During a median follow-up of 48.6 months (interquartile range, 32.3-73.3), 3 patients (7.7%) died, 1 of sudden death, 1 of heart failure, and 1 of cerebral infarction. Twenty-eight patients (71.8%) experienced 540 appropriate ICD interventions. The first appropriate ICD intervention occurred more than 2 years after initial ICD implantation in 5 patients (12.8%). Twelve patients (30.8%) suffered from electrical storm. The event-free period was significantly shorter in patients who did not have broad precordial T wave inversion ≥V1-V3 (hazard ratio = 0.39, 95% confidence interval: 0.16-0.96). No significant difference was shown in antiarrhythmic drugs and radiofrequency catheter ablation before ICD implantation between patients with and without appropriate ICD therapies (P > 0.05).CONCLUSIONS:Recurrence of sustained ventricular tachycardia/ventricular fibrillation is frequent in high-risk patients with ARVC. The prognosis is favorable for ARVC patients treated with an ICD for prevention of SCD.

2.7
3区
第一作者

Clinical cardiology 2017